The most credible answer to "what extends lifespan?" comes not from Silicon Valley clinics but from two decades of systematic animal testing run by the National Institute on Aging. Its Intervention Testing Program (ITP) has identified rapamycin as the most validated lifespan-extending compound in mammals, associated with roughly 15–20% longevity gains in mice. Meanwhile, headline-grabbing approaches like epigenetic reprogramming remain largely speculative, and one Nobel-recognized researcher argues the data point to a natural human lifespan ceiling near 110 years.
Introduction to Longevity Science
Longevity research now spans an unusually wide evidence spectrum. At one end sit drug compounds tested through rigorous, multi-decade programs in genetically diverse mice; at the other, exotic concepts like "young blood" transfusions and cellular reprogramming that capture public imagination faster than data can accumulate. A 2025 review by Dr. Richard LaFountain, covering the year's major developments, framed 2025 as one of the most productive years in human longevity science — citing breakthroughs in human trials, drug repurposing, metabolic therapeutics, and biomarker discovery. But productivity in research output is not the same as validated lifespan extension in people, and keeping those categories distinct is the central task for anyone trying to evaluate the field's claims.





